
The Race to Commercialize the World’s Most Powerful Psychedelic | WSJ
An obscure and extremely powerful psychedelic drug called 5-MeO-DMT, or BUFO, is drawing intense interest from the pharmaceutical industry, where biotech companies like AtaiBeckley and GH Research are racing to turn it into a commercially available treatment for severe mental health disorders, like depression, anxiety and PTSD.
WSJ took an inside look at how the psychedelic is being used at unregulated clinics in Mexico, and why companies are betting that it could soon turn into a billion dollar blockbuster drug.
Chapters:
0:00 The power of 5-MeO-DMT
1:31 Inside a treatment facility in Mexico
5:36 5-MeO-DMT uses and history
8:10 The psychedelic therapies market
10:46 The race to commercialize psychedelics
14:08 After the treatment in Mexico
WSJ Originals features in-depth reporting, investigations and on-the-ground journalism that uncovers the forces shaping business, politics and the world around us.
#DMT #Psychedlics #WSJ
WSJ took an inside look at how the psychedelic is being used at unregulated clinics in Mexico, and why companies are betting that it could soon turn into a billion dollar blockbuster drug.
Chapters:
0:00 The power of 5-MeO-DMT
1:31 Inside a treatment facility in Mexico
5:36 5-MeO-DMT uses and history
8:10 The psychedelic therapies market
10:46 The race to commercialize psychedelics
14:08 After the treatment in Mexico
WSJ Originals features in-depth reporting, investigations and on-the-ground journalism that uncovers the forces shaping business, politics and the world around us.
#DMT #Psychedlics #WSJ
The Wall Street Journal
The new WSJ Video takes you inside carefully selected stories and events in a visually captivating way so you can dig deeper into the news that matters to you. You’ll get breaking headlines, immersive features, interactive media and even virtual reality r...
How Equinox Turned Fitness Into a $4,000-a-Year Habit | WSJ The Economics Of
The Wall Street Journal
Pizza Hut Lost in the U.S. Now It’s Selling for $2.7B. | WSJ What Went Wrong
The Wall Street Journal